- Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
Roundhill Glp-1 & Weight Loss ETF(OZEM)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for OZEM
11/20/2026: OZEM (1-star) is currently NOT-A-BUY. Pass it for now.
The Roundhill Glp-1 & Weight Loss ETF (OZEM) provides targeted, actively managed exposure to global companies spearheading weight management and anti-obesity therapeutics. Its main strengths include pioneering thematic access and active management flexibility, though it carries notable concentration risks in top holdings like Eli Lilly and Novo Nordisk. It functions best as a satellite growth allocation for investors seeking specific exposure to the obesity treatment boom. Key risks involve high valuation multiples, regulatory pressures, and modest trading liquidity. Investors should monitor clinical updates, insurance coverage trends, and broader pharmaceutical sentiment.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The fund targets companies experiencing hyper-growth driven by breakthrough medical treatments. |
| Momentum investor | Strong fit while signal remains positive | Momentum can be powerful during positive clinical data releases or favorable sales reports for top holdings. |
| Value investor | Weak fit | Many underlying holdings trade at premium valuation multiples due to high growth expectations. |
| Dividend/Income investor | Weak fit | The portfolio focuses on capital appreciation and clinical development rather than high dividend payouts. |
| Low-risk investor | Weak fit | Concentrated exposure to a handful of pharmaceutical stocks introduces high volatility and regulatory risk. |
Investor Profile
Ideal Investor Profile
The ideal investor is a growth-oriented market participant seeking targeted exposure to the secular trend of weight-loss therapeutics who is comfortable with higher sector-specific volatility.
Suitability
Best suited for tactical, long-term thematic growth allocations rather than core passive holdings or short-term day trading.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | The fund experiences sharp price swings based on pharmaceutical trial outcomes and sector sentiment. |
| Market risk | Medium / high | Broader economic downturns can affect healthcare spending and speculative growth assets. |
| Concentration | High | A significant percentage of assets is concentrated in just a couple of major pharmaceutical companies like Eli Lilly and Novo Nordisk. |
| Tracking/expense | Medium | The 0.59% expense ratio is higher than standard passive index alternatives. |
| Liquidity | Medium / high | Lower assets under management can result in wider spreads and lower daily trading volumes. |
| Business/sector quality | Medium | Subject to intense regulatory scrutiny, clinical trial failures, and patent expirations. |
Sector & Industry Intelligence
This fund is not assigned to one sector.
Risk Analysis
Volatility
OZEM exhibits heightened historical volatility compared to broad market indices due to its specialized thematic nature and heavy reliance on a few pharmaceutical leaders.
Market Risk
Primary risks stem from clinical trial failures, regulatory setbacks, changes in drug reimbursement policies, and heavy concentration in top holdings.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Single stock | Eli Lilly and Company (LLY) | 15.28 | Serves as a primary pillar holding due to its dominant market position in GLP-1 treatments like Zepbound. |
| Single stock | Novo Nordisk A/S (NVO) | 11.64 | Provides vital core exposure to the pioneer of Wegovy and Ozempic. |
| Single stock | Pfizer Inc. (PFE) | 7.69 | Offers large-cap pharmaceutical exposure as the company develops alternative pipeline obesity treatments. |
| Single stock | Kailera Therapeutics (KLRA) | 6.3 | Represents clinical-stage innovation targeting next-generation metabolic disease therapies. |
| Single stock | CSPC Pharmaceutical Group (1093) | 5.37 | Adds international exposure via Asian pharmaceutical development in metabolic disorders. |
| Industry | Remaining Global Biotech and Pharma Holdings | 53.72 | Diversifies the portfolio across various global pharmaceutical firms and supply chain enablers. |
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type ETF | Historic Profit 16.85% | Avg. Invested days 56 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | ETF Returns Performance |

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

